menu
    • menu

    Company profile for Biohaven Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant. The most advanced product candidate from our glutamate modulation platform is trigriluzole, which we are developing for the treatment of ataxias with an initial focus on spinocerebellar ataxia, or SCA. We have rece...
    Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant. The most advanced product candidate from our glutamate modulation platform is trigriluzole, which we are developing for the treatment of ataxias with an initial focus on spinocerebellar ataxia, or SCA. We have received orphan drug designation from the FDA for trigriluzole in SCA, and we began a Phase 2/3 clinical trial in SCA in December 2016 and expect to report topline results in early 2018.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biohaven PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Biohaven Pharmaceuticals, Inc 234 Church Street New Haven, CT 06510
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biohavenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biohaven-pharmaceuticals-inc/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/biohavenpharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biohaven Shares BHV-1510 Safety Data with Cemiplimab at ESMO 2025
    Biohaven Shares BHV-1510 Safety Data with Cemiplimab at ESMO 2025

    11 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-presents-clinical-safety-and-efficacy-data-for-bhv-1510-a-next-generation-trop2-antibody-drug-conjugate-in-combination-with-cemiplimab-at-the-2025-european-society-for-medical-oncology-esmo-immuno-oncology-congress-302638503.html

    PR NEWSWIRE
    11 Dec 2025
    Share Share
    Biohaven Completes Upsized Public Offering, Raises $200M
    Biohaven Completes Upsized Public Offering, Raises $200M

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-announces-closing-of-upsized-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-generating-gross-proceeds-of-approximately-200m-302614987.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Biohaven Prices $175M Public Offering Of Common Shares
    Biohaven Prices $175M Public Offering Of Common Shares

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-announces-pricing-of-175-million-public-offering-of-common-shares-302612931.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    Biohaven Announces Proposed Public Offering Of Common Shares
    Biohaven Announces Proposed Public Offering Of Common Shares

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-announces-proposed-public-offering-of-common-shares-302612115.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Biohaven Unveils Q3 2025 Financials & Business Updates
    Biohaven Unveils Q3 2025 Financials & Business Updates

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-reports-third-quarter-2025-financial-results-and-recent-business-developments-302609810.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    FDA Rejects Biohaven Approval Request, Triggering Cost Cutting
    FDA Rejects Biohaven Approval Request, Triggering Cost Cutting

    06 Nov 2025

    // BIOSPACE

    https://www.biospace.com/business/biohaven-cuts-r-d-spending-by-60-after-fda-rejection-of-drug-for-rare-neurodegenerative-disease

    BIOSPACE
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search